Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease

International Journal of Molecular Medicine

Volumn 20, Issue 2, 2007, Pages 161-167

  Yukawa, Tomomi ^a   Oshitani, Nobuhide ^a   Yamagami, Hirokazu ^a   Watanabe, Kenji ^a   Higuchi, Kazuhide ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunohistochemistry; Inflammatory bowel disease; Vasoactive intestinal peptide receptor 1

Indexed keywords

CYTOKINE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VIPR1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; ENTERITIS; FEMALE; HUMAN; INTESTINE; MALE; METABOLISM; MIDDLE AGED; MUCOSA; TH1 CELL; TH2 CELL; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MALE; MIDDLE AGED; MUCOUS MEMBRANE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TH1 CELLS; TH2 CELLS; TISSUE DISTRIBUTION;

EID: 35449007750     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.2.161     Document Type: Article

References (28)

1. Baldassano RN, Schreiber S, Johnston RB Jr, Fu RD, Muraki T and MacDermott RP: Crohn's disease monocytes are primed for accentuated release of toxic oxygen metabolites. Gastroenterology 105: 60-66, 1993.
2. Monteleone I, Vavassori P, Biancone L, Monteleone G and Pallone F: Immunoregulation in the gut: success and failures in human disease. Gut 50 (suppl 3): 60-64, 2002.
3. Klein TW, Newton C and Friedman H: Cannabinoid receptors and immunity. Immunol Today 19: 373-381, 1998.
4. Bijlsma JWJ, Cutolo M, Masi AT and Chicanza IC: The neuroendocrine immune basis of rheumatic disease. Immunol Today 20: 298-301, 1999.
5. Gomariz RP, Martinez C, Abad C, Leceta J and Delgado M: Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 7: 89-111, 2001.
6. Kimura M, Masuda T, Hiwatashi N, Toyota T and Nagura H: Change in neuropeptide-nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int 44: 624-634, 1994.
7. Niessner M and Volk BA: Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101: 428-435, 1995.
8. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M and Gomariz RP: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mouse model of Crohn's disease. Gastroenterology 124: 2003.
9. Satsangi J, Silvergerg MS, Vermeire S and Colombel J-F: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implication. Gut 55: 749-753, 2006.
10. Truelove SC and Witts LI: Cortisone in ulcerative colitis. BMJ 2: 1041-1048, 1955.
11. Best WR, Becktel JM, Singleton JW, et al: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444, 1976.
12. Fuxe K, Hokfelt T, Said SI and Mutt V: Vasoactive intestinal polypeptide and the nervous system; immunohistochemical evidence of localization in central and peripheral neurons, particularly intracortical neurons of the cerebral cortex. Neurosci Lett 5: 241-246, 1977.
13. Covineau A, Rouyer-Fessard C, Darmoul D, Maoret JI, Carrero I, Ogier-Denis E and Laburthe M: Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 200: 769-776, 1994.
14. Ishihara T, Shigemoto R, Mori K, Takahashi K and Nagata S: Functional expression and tissue distribution of a novel receptor for vasoactive intestinal peptide. Neuron 8: 811-819, 1992.
15. Delgado M and Ganea D: Is vasoactive intestinal peptide a type2 cytokine? J Immunol 166: 2907-2912, 2001.
16. Dewit D, Gourlet P, Amraoui Z, Vertongen P, Willems F, Robberetch P and Goldman M: The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol Lett 60: 57-60, 1998.
17. Martinez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D and Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukocyte Biol 63: 591-601, 1998.
18. Xin Z and Sriram S: Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J Neuroimmunol 89: 206-212, 1998.
19. Delgado M: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia. Biochem Biophys Res Commun 297: 1181-1185, 2002.
20. Ganea D: Regulatory effects of VIP on cytokine production in central and peripheral lymphoid organs. Adv Neuroimmunol 6: 61-74, 1996.
21. Delgado M, Pozo D and Ganea D: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56: 249-290, 2004.
22. Schulz S, Rocken C, Mawrin C, Weise W, Hollt V and Schulz S: Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptor in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res 10: 8235-8242, 2004.
23. Todorovic V, Janic B, Koko V, Micev M, Nikolic JA, Ratkovic M, Leposavic G, Jankovic T, Knezevic-Usaj S and Milicevic Z: Colonic vasoactive intestinal polypeptide (VIP) in ulcerative colitis - a radioimmunoassay and immunohistochemical study. Hepatogastroenterology 43: 483-488, 1996.
24. Koch TR, Carney JA and Go VL: Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel disease. Dig Dis Sci 4: 369-376, 1987.
25. Kubota Y, Petras RE and Ottaway CA: Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease. Gastroenterology 102: 1242-1251, 1992.
26. Newman R, Cuan N, Hampartzoumian T, Connor SJ, Lloyd AR and Grimm MC: Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin Exp Immunol 139: 411-420, 2005.
27. Nielson OH, Koppen T, Rudiger N, Horn T, Eriksen J and Kirman I: Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci 9: 1786-1792, 1998.
28. Inoue S, Matsumoto T, Iida M, et al: Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 94: 2441-2446, 1999.